Related references
Note: Only part of the references are listed.Robust Design and Analysis of Clinical Trials With Nonproportional Hazards: A Straw Man Guidance From a Cross-Pharma Working Group
Satrajit Roychoudhury et al.
STATISTICS IN BIOPHARMACEUTICAL RESEARCH (2023)
Nonproportional Hazards-An Evaluation of the MaxCombo Test in Cancer Clinical Trials
Yuan-Li Shen et al.
STATISTICS IN BIOPHARMACEUTICAL RESEARCH (2023)
Alternative Analysis Methods for Time to Event Endpoints Under Nonproportional Hazards: A Comparative Analysis
Ray S. Lin et al.
STATISTICS IN BIOPHARMACEUTICAL RESEARCH (2020)
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer The MYSTIC Phase 3 Randomized Clinical Trial
Naiyer A. Rizvi et al.
JAMA ONCOLOGY (2020)
Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study
M. Moehler et al.
ANNALS OF ONCOLOGY (2020)
Statistical and practical considerations in designing of immuno-oncology trials
Pralay Mukhopadhyay et al.
JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2020)
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC
Roy S. Herbst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
Kohei Shitara et al.
JAMA ONCOLOGY (2020)
Methods for Accommodating Nonproportional Hazards in Clinical Trials: Ready for the Primary Analysis?
Boris Freidlin et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Quantification of Long-term Survival Benefit in a Comparative Oncology Clinical Study
Miki Horiguchi et al.
JAMA ONCOLOGY (2018)
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Louis Fehrenbacher et al.
LANCET (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical Trials
Julien Peron et al.
JAMA ONCOLOGY (2016)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis
Hajime Uno et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome
Patrick Royston et al.
BMC MEDICAL RESEARCH METHODOLOGY (2013)
Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
Antoni Ribas et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
Patricia Guyot et al.
BMC MEDICAL RESEARCH METHODOLOGY (2012)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Generalized pairwise comparisons of prioritized outcomes in the two-sample problem
Marc Buyse
STATISTICS IN MEDICINE (2010)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Share Paper
